SIGA

SIGA Technologies, Inc. is a prominent New York-based commercial-stage biopharmaceutical firm dedicated to the development and commercialization of innovative therapeutics for infectious diseases, particularly through its flagship antiviral treatment, TPOXX, which is approved for the treatment of smallpox. With a strong emphasis on biodefense and strategic partnerships with government entities, SIGA plays a crucial role in bolstering public health readiness against biothreats. The company's focus on addressing both current and emerging global health issues positions it as a vital player in enhancing response capabilities within the biopharmaceutical landscape.